US OptionsDetailed Quotes
CARA241220P2500
- 0.00
- 0.000.00%
15min DelayClose Nov 29 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-722.37%PremiumDec 20, 2024Expiry Date2.20Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.14Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cara Therapeutics Stock Discussion
Sign in to post a comment
$Cara Therapeutics (CARA.US)$
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
1
$Cara Therapeutics (CARA.US)$
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
3
$Cara Therapeutics (CARA.US)$
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
Cara Therapeutics' low P/S ratio reflects its declining revenues and bleak future growth projection. Per investors, the company's future may not yield a significant revenue improvement.
1
$Cara Therapeutics (CARA.US)$
Small position to start. I'll swing this one.
Small position to start. I'll swing this one.
5
25
$Cara Therapeutics (CARA.US)$
Potential to go higher, but will need to break 4.80 and hold above 4.60. Depending on how it does today, this could be a swing play
Potential to go higher, but will need to break 4.80 and hold above 4.60. Depending on how it does today, this could be a swing play
2
No comment yet
70794146 :